Biological
GNR-068
GNR-068 is a biological therapy with 2 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
50%
Ph phase_1
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed150%
active_not_recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
active_not_recruitingphase_3
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
NCT06488664
completedphase_1
A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers
NCT06481215
Clinical Trials (2)
Showing 2 of 2 trials
NCT06488664Phase 3
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
NCT06481215Phase 1
A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2